Published 1 day ago • loading... • Updated 8 hours ago

Study shows benefits of GLP-1 drugs for kidney transplant recipients with type 2 diabetes

Kidney transplant recipients with type 2 diabetes who took GLP-1 agonists had a 49% lower chance of organ failure compared to those who did not take the drugs.
Those patients had a 31% reduced risk of dying within five years of beginning the medication.
The study revealed an increased risk of diabetic retinopathy among GLP-1 users, highlighting the need for eye health monitoring.
The research provided strong evidence for the safety and effectiveness of GLP-1 medications for these patients.

Insights by Ground AI

Does this summary seem wrong?

49 Articles

All

Left

Center

Right

News Medical

Study shows benefits of GLP-1 drugs for kidney transplant recipients with type 2 diabetes

Kidney transplant recipients with type 2 diabetes treated with a new class of anti-obesity drugs were less likely to experience organ failure and survived longer, a new study shows.

23 hours ago·United States

Read Full Article

The Laconia Daily Sun

+36 Reposted by 36 other sources

Anti-Obesity Drugs Benefit Kidney Transplant Recipients with Type 2 Diabetes

Drugs found to be safe and effective overall despite some risk of eye damage

1 day ago

Read Full Article

MedPage Today

Use of GLP-1 Drugs for Obesity Linked to Lower Risk of Glaucoma

(MedPage Today) -- Use of GLP-1 receptor agonists for obesity was associated with a reduced risk of primary open-angle glaucoma (POAG) and ocular hypertension compared with other weight-loss medications, a retrospective cohort study suggested...

1 day ago·New York, United States

Read Full Article

bipns.com

Microdosing GLP-1 Drugs – HealthyWomen

March 3 -7, 2025, is Obesity Care Week. The term “microdosing” probably makes you think of psychedelic drugs — us too. But the latest trend in microdosing involves taking small amounts of the popular weight-loss medications known as GLP-1s. GLP-1 drugs have revolutionized the way we treat Type 2 diabetes and obesity. The injectable medications mimic a hormone made in the gut called glucagon-like peptide-1 (GLP-1), which helps manage blood sugar,…

8 hours ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year